Novan, Inc. (NOVN) News
Filter NOVN News Items
NOVN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest NOVN News From Around the Web
Below are the latest news stories about NOVAN INC that investors may wish to consider to help them evaluate NOVN as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayWe're starting Thursday with a detailed look at all of the biggest pre-market stock movers worth keeping an eye on today! |
Investors Holding Back On Novan, Inc. (NASDAQ:NOVN)Novan, Inc.'s ( NASDAQ:NOVN ) price-to-sales (or "P/S") ratio of 1.1x might make it look like a buy right now compared... |
Novan to Provide Corporate Update at its 2023 Annual Meeting of StockholdersDURHAM, N.C., June 05, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will host a live audio webcast of the Company’s 2023 Annual Meeting of Stockholders (“ASM”) being held on Tuesday, June 6, 2023 at 9:30 a.m. Eastern Time in a virtual format. The Company also announced that its Chairman, President and CEO, Paula Brown Stafford, will provide a corporate update on the Company after the conclusion of the ASM, including the Company’s current |
Novan Focuses Strategic Direction and Announces Restructuring– Company directing resources on the potential approval of berdazimer gel, 10.3% (SB206) for molluscum contagiosum – – Process to explore a sale or out-license of commercial assets or other business transaction continues – – Continued progress toward PDUFA goal date of January 5, 2024, for berdazimer gel, 10.3% – DURHAM, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that following an evaluation of its commercial and developmental st |
NOVN: Counting Down to PDUFABy John Vandermosten, CFA NASDAQ:NOVN READ THE FULL NOVN RESEARCH REPORT 1Q:23 Financial and Operational Results On May 15th, 2023, Novan Inc. (NASDAQ:NOVN) reported 1Q:23 financial and operational results in a press release and in the filing of Form 10-Q . A conference call and webcast were subsequently held to update investors on recent developments. The call highlighted the performance of the |
Q1 2023 Novan Inc Earnings CallQ1 2023 Novan Inc Earnings Call |
Novan Reports First Quarter 2023 Financial Results and Provides Corporate Update– Continued progress toward PDUFA goal date of January 5, 2024, for berdazimer gel, 10.3% (SB206) – – Strong prescription growth across three promoted products – – Company to host conference call today at 8:30 a.m. ET – DURHAM, N.C., May 15, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced its financial and operating results for the first quarter ended March 31, 2023, and provided a corporate update. The Company will host a conference call and webca |
Novan to Report First Quarter 2023 Financial Results on May 15, 2023DURHAM, N.C., May 08, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its first quarter 2023 financial results on Monday, May 15th. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day. The call will be led by Paula Brown Stafford, President and Chief Executive Officer of Novan, who will be joined by additional members of the Novan mana |
Novan Announces Publication of Psoriasis Patient Data Demonstrating Need for Rapid Symptom Improvement¹Published results from a National Psoriasis Foundation-fielded survey included responses from more than 400 patients across US1 Findings highlight impact on patient adherence of early onset of improvement with topical psoriasis medications1 WYNZORA® (calcipotriene and betamethasone dipropionate) Cream demonstrates rapid onset of action with results seen in efficacy, scale and itch as early as 1 week and continued improvement at 8 weeks2,3 DURHAM, N.C. and COPENHAGEN, Denmark, April 27, 2023 (GLO |
Novan to Host Analyst and Investor Event: A Discussion of Molluscum’s Unmet Need with Pediatric Dermatologist Jeffrey Sugarman, MD, PhDLive moderated webcast with members of the Novan management team and dermatological key opinion leader, Dr. Jeffrey Sugarman on Tuesday, April 25th at 2:00 PM ETDURHAM, N.C., April 20, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will host an Analyst and Investor Event: A Discussion of Molluscum’s Unmet Need with Pediatric Dermatologist Jeffrey Sugarman, MD, PhD, on Tuesday, April 25, 2023, at 2:00 PM ET. For the event, Paula Brown Staff |